Join
Live feed
·
PRReleasevia Quantisnow
Aravive Inc. logo

Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma

ByQuantisnow·Wall Street's wire, on your screen.
ARAV· Aravive Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARAV (Aravive Inc.) and more on Quantisnow.